Age-Related Vision Dysfunction Pipeline Analysis Report 2025
Description
Age-related vision dysfunction (ARVD) refers to a group of age-related conditions, including presbyopia, that impair visual function over time. According to Maria Markoulli et al., 2024, the global all-ages prevalence of functional presbyopia is projected to stabilize at 24.1% by 2030, impacting approximately 2.1 billion people due to population growth and rising myopia. As per the age-related vision dysfunction pipeline analysis by Expert Market Research, therapeutic developments are increasingly focused on gene therapies, complement inhibitors, and long-acting ocular treatments. The growth in the treatment landscape is expected in the coming years, particularly driven by technological advancements, rising awareness, and the expanding aging population.
Report Coverage
The Age-Related Vision Dysfunction Pipeline Analysis Report by Expert Market Research gives comprehensive insights into age-related vision dysfunction therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for age-related vision dysfunction. The age-related vision dysfunction report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The age-related vision dysfunction pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with age-related vision dysfunction treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to age-related vision dysfunction.
Age-Related Vision Dysfunction Pipeline Outlook
Age-related vision dysfunction refers to a decline in visual function due to aging, commonly including conditions such as age-related macular degeneration (AMD), cataracts, and presbyopia. It results from retinal cell degeneration, oxidative stress, and reduced ocular blood flow, leading to blurred or distorted vision and difficulty in low-light conditions.
Treatments for age-related vision dysfunction include anti-VEGF injections, cataract surgery, and corrective lenses. Pharmacological strategies focus on slowing disease progression and improving visual acuity through targeted therapies. According to J Jesus Rodriguez-Cruz et al., 2025, Brolucizumab is a notable pipeline drug. It is a small, humanized antibody fragment targeting all VEGF-A isoforms, providing enhanced retinal penetration, high binding affinity, reduced ocular inflammation, and improved best-corrected visual acuity.
Age-Related Vision Dysfunction Epidemiology
The pipeline is expanding to address the growing prevalence of presbyopia and other vision impairments. According to Maria Markoulli et al., 2024, functional presbyopia affected 1.8 billion people globally in 2015, with prevalence projected to reach 2.1 billion by 2030 due to population growth. Prabhakar Singh et al., 2025, reported that presbyopia accounted for 71.8% of near visual impairment in the Brazilian Amazon, with symptomatic onset typically between ages 40 and 45 and near-universal prevalence by 60. Rising life expectancy, an aging global population, and increased digital screen usage are driving demand for novel therapeutic interventions and innovative drug candidates targeting this condition.
Age-Related Vision Dysfunction – Pipeline Therapeutic Assessment
This section of the report covers the analysis of age-related vision dysfunction drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
The age-related vision dysfunction pipeline analysis report covers 50+ drug analyses based on drug classes:
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total age-related vision dysfunction clinical trials of 50%. It is followed by phase III at 33% and phase I at 16%. This distribution underscores the pivotal role of phase II in advancing therapeutic candidates, with phase III focusing on efficacy and safety validation.
Age-Related Vision Dysfunction Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the age-related vision dysfunction pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The age-related vision dysfunction report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for age-related vision dysfunction. According to Macular Degeneration Research in July 2025, tyrosine kinase inhibitors are emerging as a promising drug class for wet age-related macular degeneration. These drugs target enzymes upstream of vascular endothelial growth factor to prevent abnormal blood vessel growth. Implants delivering these inhibitors have shown potential to reduce the frequency of injections. Moreover, combination therapies targeting VEGF and inflammatory pathways, including interleukin-6 or the complement system, are under evaluation to enhance visual outcomes and retinal protection.
Age-Related Vision Dysfunction Clinical Trials – Key Players
The EMR report for the age-related vision dysfunction pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed age-related vision dysfunction therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in age-related vision dysfunction clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for age-related vision dysfunction. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of age-related vision dysfunction drug candidates.
Drug: Iptacopan (LNP023)
Iptacopan (LNP023) is a highly potent oral factor B inhibitor being developed by Novartis Pharmaceuticals for the treatment of age-related macular degeneration (AMD). This Phase 2, multicenter, randomized, participant and investigator-masked, placebo-controlled study is examining Iptacopan’s safety and efficacy in preventing the progression of early or intermediate AMD to incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD. The study is enrolling approximately 146 participants worldwide, focusing on high-risk patients.
Genetic: ADVM-022
ADVM-022 is a gene therapy drug sponsored by Adverum Biotechnologies, Inc., and it is designed for treating neovascular (wet) age-related macular degeneration (nAMD). This Phase 2 study is examining the safety, tolerability, and efficacy of a single intravitreal injection of ADVM-022 at two different doses, alongside prophylactic corticosteroid regimens. The drug encodes aflibercept, an anti-VEGF protein, enabling retinal cells to continuously produce it, aiming to reduce frequent injections and improve long-term vision outcomes in nAMD patients.
Key Questions Answered in the Age-Related Vision Dysfunction Pipeline Insight Report
The Age-Related Vision Dysfunction Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for age-related vision dysfunction. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into age-related vision dysfunction collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Global Clinical Trials Market
Age-Related Macular Degeneration Market
Macular Degeneration Drug Pipeline Analysis Report
Dry Age-Related Macular Degeneration Pipeline Analysis Report
Report Coverage
The Age-Related Vision Dysfunction Pipeline Analysis Report by Expert Market Research gives comprehensive insights into age-related vision dysfunction therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for age-related vision dysfunction. The age-related vision dysfunction report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The age-related vision dysfunction pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with age-related vision dysfunction treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to age-related vision dysfunction.
Age-Related Vision Dysfunction Pipeline Outlook
Age-related vision dysfunction refers to a decline in visual function due to aging, commonly including conditions such as age-related macular degeneration (AMD), cataracts, and presbyopia. It results from retinal cell degeneration, oxidative stress, and reduced ocular blood flow, leading to blurred or distorted vision and difficulty in low-light conditions.
Treatments for age-related vision dysfunction include anti-VEGF injections, cataract surgery, and corrective lenses. Pharmacological strategies focus on slowing disease progression and improving visual acuity through targeted therapies. According to J Jesus Rodriguez-Cruz et al., 2025, Brolucizumab is a notable pipeline drug. It is a small, humanized antibody fragment targeting all VEGF-A isoforms, providing enhanced retinal penetration, high binding affinity, reduced ocular inflammation, and improved best-corrected visual acuity.
Age-Related Vision Dysfunction Epidemiology
The pipeline is expanding to address the growing prevalence of presbyopia and other vision impairments. According to Maria Markoulli et al., 2024, functional presbyopia affected 1.8 billion people globally in 2015, with prevalence projected to reach 2.1 billion by 2030 due to population growth. Prabhakar Singh et al., 2025, reported that presbyopia accounted for 71.8% of near visual impairment in the Brazilian Amazon, with symptomatic onset typically between ages 40 and 45 and near-universal prevalence by 60. Rising life expectancy, an aging global population, and increased digital screen usage are driving demand for novel therapeutic interventions and innovative drug candidates targeting this condition.
Age-Related Vision Dysfunction – Pipeline Therapeutic Assessment
This section of the report covers the analysis of age-related vision dysfunction drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
The age-related vision dysfunction pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
- Peptides
- Polymers
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total age-related vision dysfunction clinical trials of 50%. It is followed by phase III at 33% and phase I at 16%. This distribution underscores the pivotal role of phase II in advancing therapeutic candidates, with phase III focusing on efficacy and safety validation.
Age-Related Vision Dysfunction Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the age-related vision dysfunction pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The age-related vision dysfunction report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for age-related vision dysfunction. According to Macular Degeneration Research in July 2025, tyrosine kinase inhibitors are emerging as a promising drug class for wet age-related macular degeneration. These drugs target enzymes upstream of vascular endothelial growth factor to prevent abnormal blood vessel growth. Implants delivering these inhibitors have shown potential to reduce the frequency of injections. Moreover, combination therapies targeting VEGF and inflammatory pathways, including interleukin-6 or the complement system, are under evaluation to enhance visual outcomes and retinal protection.
Age-Related Vision Dysfunction Clinical Trials – Key Players
The EMR report for the age-related vision dysfunction pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed age-related vision dysfunction therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in age-related vision dysfunction clinical trials:
- Adverum Biotechnologies, Inc.
- Novartis Pharmaceuticals
- Eyestem Research Pvt. Ltd.
- Bayer
- Regeneron Pharmaceuticals
- Roche
- Alcon
- Kodiak Sciences
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for age-related vision dysfunction. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of age-related vision dysfunction drug candidates.
Drug: Iptacopan (LNP023)
Iptacopan (LNP023) is a highly potent oral factor B inhibitor being developed by Novartis Pharmaceuticals for the treatment of age-related macular degeneration (AMD). This Phase 2, multicenter, randomized, participant and investigator-masked, placebo-controlled study is examining Iptacopan’s safety and efficacy in preventing the progression of early or intermediate AMD to incomplete retinal pigment epithelium and outer retinal atrophy (iRORA) or late AMD. The study is enrolling approximately 146 participants worldwide, focusing on high-risk patients.
Genetic: ADVM-022
ADVM-022 is a gene therapy drug sponsored by Adverum Biotechnologies, Inc., and it is designed for treating neovascular (wet) age-related macular degeneration (nAMD). This Phase 2 study is examining the safety, tolerability, and efficacy of a single intravitreal injection of ADVM-022 at two different doses, alongside prophylactic corticosteroid regimens. The drug encodes aflibercept, an anti-VEGF protein, enabling retinal cells to continuously produce it, aiming to reduce frequent injections and improve long-term vision outcomes in nAMD patients.
Key Questions Answered in the Age-Related Vision Dysfunction Pipeline Insight Report
- Which companies/institutions are leading the age-related vision dysfunction drug development?
- Which company is leading the age-related vision dysfunction pipeline development activities?
- What is the current age-related vision dysfunction commercial assessment?
- What are the opportunities and challenges present in the age-related vision pipeline landscape?
- What is the efficacy and safety profile of age-related vision dysfunction pipeline drugs?
- Which company is conducting major trials for age-related vision dysfunction drugs?
- Which companies/institutions are involved in age-related vision dysfunction collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in age-related vision dysfunction?
The Age-Related Vision Dysfunction Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for age-related vision dysfunction. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into age-related vision dysfunction collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Global Clinical Trials Market
Age-Related Macular Degeneration Market
Macular Degeneration Drug Pipeline Analysis Report
Dry Age-Related Macular Degeneration Pipeline Analysis Report
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Age-Related Vision Dysfunction
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Age-Related Vision Dysfunction
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Age-Related Vision Dysfunction: Epidemiology Snapshot
- 5.1 Age-Related Vision Dysfunction Incidence by Key Markets
- 5.2 Age-Related Vision Dysfunction – Patients Seeking Treatment in Key Markets
- 6 Age-Related Vision Dysfunction: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Age-Related Vision Dysfunction: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Age-Related Vision Dysfunction, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Age-Related Vision Dysfunction Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Age-Related Vision Dysfunction Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Genetic: Ixo-vec
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Other Drugs
- 11 Age-Related Vision Dysfunction Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: Iptacopan (LNP023)
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Genetic: ADVM-022
- 11.2.3 Other Drugs
- 12 Age-Related Vision Dysfunction Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Drug:
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Age-Related Vision Dysfunction Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Age-Related Vision Dysfunction, Key Drug Pipeline Companies
- 14.1 Adverum Biotechnologies, Inc.
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Novartis Pharmaceuticals
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Eyestem Research Pvt. Ltd.
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Bayer
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Regeneron Pharmaceuticals
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Roche
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Alcon
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Kodiak Sciences
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
